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Cationic carbosilane dendrimers and dendrons labelled with one fluorescein unit have been 
synthesized. For dendrimers (generations 1-3), a random procedure was followed by successive addition 
of two types of thiol compounds to vinyl terminated derivatives, first one with –NH3Cl and second one 
with –NMe2HCl functions, subsequent reaction with FITC and finally by quaternization with MeI. For 
dendrons, the use of compounds with a -NH2 group at the focal point and NMe2 functions at the periphery 
allowed us to obtain the corresponding fluoresceinated cationic derivatives. The toxicity of these dendritic 
molecules was studied by MTT and their interaction with siRNA Nef by electrophoresis. Finally, second 
generation dendrimer and its dendriplexes with siRNA Nef were chosen as a model to analyze their in 
vivo biodistribution in a model of BALB/c mice. The highest levels for dendriplexes were found in spleen, 
and liver, followed by those in lymph nodes, while lower levels were found in kidneys. This distribution is 
in accordance with long circulation times. 




Nanomedicine can be defined as the use of macromolecules on the nanoscale range for diagnostics 
and/or therapeutics. As an example, nanotechnology-based systems can be used to deliver therapeutic 
entities such as small-molecule drugs, peptides, proteins, and nucleic acids, either alone or in 
combinations.1-3 The biological transport processes are affected by: i) the physical attributes of the 
nanocarriers, as for example size, shape, and flexibility; ii) their chemical characteristics, including for 
instance the incorporation of active ligands for recognition by and triggering of biological receptors;4 as 
well as iii) their biologic response, drug toxicity, bioavailability, cell death, and modification of drug 
pharmacokinetics.5-7  
Polymers and macromolecular aggregates have been vastly employed to effectively protect, transport 
and deliver drugs to target sites.8-14 Among them, the characteristics of dendritic macromolecules, as well-
defined size and structure, flexibility, monodispersity and multivalent molecular surface,15-22 make them 
very attractive for biomedical applications.23-31 Furthermore, their multivalency can be employed to obtain 
multitasking therapeutics. The presence of a director group altogether with adequate active functions have 
served for treating  infectious diseases,32, 33 or cancer34 by targeting particular tissues. 
Gene therapy is the transportation of functional genetic material, such as plasmids, nucleic acids (DNA 
and RNA) and oligonucleotides to the intracellular milieu in order to treat or prevent disesases.35 The 
instability of nucleic acids in the bloodstream requires the use of carriers, which compact them and 
prevent their degradation. For this purpose, macromolecular systems are used and particularly cationic 
derivatives that are able to form nanoconjugates with nucleic acids through electrostatic interactions. 
Hence, cationic dendrimers can be employed for this application.36-44 The understanding of their 
behaviour in cellular uptake and biodistribution should be very helpful to determine the border of their 
application and the need to introduce modifications on the molecule to improve their behaviour. It has 
been reported that circulation time, route of elimination, and organ accumulation strongly depends on 
dendrimers generation (size), charge and terminal groups.45-47 This knowledge is of prime importance for 
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the rationzalization of dendriplexes design and utility, and is evaluated with compounds decorated with 
chromophore units. 
Our group is interested in biomedical applications of carbosilane dendrimers and water-soluble cationic 
derivatives have been used as delivery vectors,48-52 binding oligonucleotides and siRNA and transporting 
them to the interior of a range of cell types.48-52 Cationic carbosilane dendrimers with two ammonium 
groups and a Si-O bond per branch were able to successfully transfect human astrocytes crossing an in 
vitro blood brain barrier (BBB) model.53 However, these dendrimers were water unstable due to the 
presence of this Si-O bond very close to the dendrimer surface, making difficult their manipulation, 
modification and hence, their widespread application.51 Other related systems with a Si-C bond instead of 
the Si-O bond were obtained by hydrosilylation reactions, although they were not as effective as RNA 
transfecting agents.54 For those reasons, we have looked for dendrimers decorated with one cationic 
charge per branch and presenting non hydrolysable bonds. As synthetic strategy we have chosen the thiol-
ene addition that also facilitates the access to heterofunctionalized systems.55 Moreover, we have 
demonstrated that a second generation cationic dendrimer so synthesized and labelled with a fluorescein 
moiety form a stable dendriplex with siRNA Nef and crosses the BBB in a BALB/c mouse model, without 
histological and morphological changes in different brain regions.56 
In view of these results, herein we have spread our research on heterofunctionalized dendritic systems to 
the preparation of new dendrimers and dendrons with a fluorescein fragment on the periphery or at the 
focal point, respectively. These systems have been evaluated as carriers in gene therapy by studying their 
interaction with siRNA Nef and their biodistribution in vivo in a model of BALB/c mice (both dendrimer 
and dendriplex). For this last goal we have chosen the second generation dendrimer labelled with 
fluorescein. 
 
2. Results and Discussion 
2.1. Synthesis of FITC labelled dendrimers and dendrons. 
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To obtain dendrimers and dendrons with cationic moieties –NMe3
+ and with a fluorescein group we 
followed a random approach for dendrimers and a controlled procedure for dendrons. In both cases, the 
synthesis was performed from compounds containing one –NH2 group and several –NMe2 functions, 
employing the typical addition of a –NH2 moiety to the isothiocyanate function of modified FITC (5’-
isothiocyanatefluorescein) and then quaternization with MeI of dimethylamino (–NMe2) peripheral 
groups. The amine groups on the periphery of carbosilane dendrimers and dendrons were introduced by 
thiol-ene click chemistry, which is a simple procedure to achieve this goal in carbosilane dendritic 
molecules with high yields.57-60 
The reaction of vinyl dendrimers GnO3Vm (n = 1, m = 6; n = 2, m = 12; n = 3, m =24)
59 with one 
equivalent of cysteamine hydrochloride HS(CH2)2NH3Cl, under UV irradiation, allowed the introduction 
of one of this functions on the periphery of dendrimers (Scheme 1). The compounds [GnO3(NH3)Vm-1]
+ (n 
= 1, m = 6 (1); n = 2, m = 12 (2); n = 3, m = 24 (3)) thus formed were analyzed by NMR spectroscopy. 
The 1H NMR spectra clearly showed the formation of the new chain Si(CH2)2S by mean of the resonances 
at δ ca. 0.9 and δ ca. 2.5 for the methylene bonded to the Si and S atom, respectively.55 Also, in this 
spectra were observed the resonances of the peripheral chain S(CH2)2N at δ ca. 2.9 and δ ca. 3.2. The 
integral relationship between these resonances and those belonging to the remaining vinyl functions 
confirms the introduction of approximately one group. Next, addition of excess of the second thiol, 
HS(CH2)2NMe2·HCl, transformed the remaining vinyl functions and the corresponding dendrimers 
[GnO3(NH3)(NMe2H)m-1]
m+ (n = 1, m = 6 (4); n = 2, m = 12 (5); n = 3, m = 24 (6)) were obtained 
(Scheme 1). The monitorization of the reaction by NMR spectroscopy showed the disappearance of the 
vinyl groups. However, in the 1H NMR spectra the methylene groups belonging to both type of peripheral 
chains (CH2-NH3
+ and CH2-NMe2H
+) were not distinguished due to overlapping of the signals. On the 
other hand, 13C NMR spectra showed the resonances corresponding for the outer chains becoming from 
the different thiols employed. In the 15N NMR spectroscopy, the only resonance observed was that 
corresponding to the cationic –NMe2H
+ group.  
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Following the same protocol for second generation dendrimer G2O3V12, but modifying the ratio of thiols 
HS(CH2)2NH3Cl/HS(CH2)2NMe2HCl, the heterofunctionalized cationic dendrimers 
[G2O3(NH3)p(NMe2H)12-p]
12+ (p = 2 (5b); p = 4 (5c) were prepared (Scheme S1, Supporting Information). 
These compounds showed analogous NMR data to those of derivatives 4-6. These compounds could be 
useful to introduce simultaneously additional functionalities on dendritic periphery apart from a dye, such 
as a drug or a targeting moiety. 
 
Scheme 1. Synthesis of generation 1-3 cationic carbosilane dendrimers labelled with fluorescein 
[GnO3(NMeFlu)(NMe3)m-1]
m+ (n = 1, m = 6 (10); n = 2, m = 12 (11); n = 3, m =24 (12)). i) 1 eq. 
HS(CH2)2NH3Cl, DMPA, UV; ii) excess HS(CH2)2NMe2HCl, DMPA, UV; iii) FITC, excess NEt3; iv) 
MeI. 
The neutral labelled derivatives [GnO3(NMeFlu)(NMe2)m-1] (n = 1, m = 6 (7); n = 2, m = 12 (8); n = 3, 
m = 24 (9)) were formed by addition of 5’-fluorescein isothiocyanate (FITC) to compounds 4-6 (Scheme 
1), in the presence of excess NEt3. The finalization of the reaction was checked by the negative result of 
Kaiser’s test. 2D-DOSY-NMR experiments were especially useful to confirm the formation of these 
compounds as just one diffusion coefficient for dendrimer and fluorescein fragments was observed. 
However, for the initial mixture of dendrimer and FITC two different diffusion values were obtained, 
being clearly higher the one belonging to the FITC molecule due to its smaller size. Afterward, to 
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compounds 7-9, without purification, slight excess of MeI was added to furnish [GnO3(NMeFlu)(NMe3)m-
1]
(m-1)+ (n = 1, m = 6 (10); n = 2, m = 12 (11); n = 3, m = 24 (12)). Dendrimers 10-12 were obtained as 
orange solids soluble in DMSO and water with high yields (> 80 %). NMR spectroscopy confirmed 
formation of compounds 10-12, mainly by the shifting to higher frequency of the resonances belonging to 
the groups bound to the cationic nitrogen atoms (CH2 and Me). The addition of MeI also produced 
methylation of the nitrogen atom that acts as linker to the dendritic structure (C(S)N(Me)CH2, ca. 2.80 
ppm in 1H NMR spectra and ca. 42.0 ppm in 13C NMR spectra, respectively; Figure S5 in Supporting 
Information). This transformation does not modify the fluorescence properties of the fluorescein moiety. 
As for neutral compounds, 2D-DOSY-NMR spectra showed a unique diffusion coefficient for the whole 
molecule, confirming the bonding of the cromophore in these dendrimers (Figure S6, Supporting 
Information) 
For the synthesis of related dendrons we started from compounds NH2Gn(NMe2)m (n = 2, m = 4; n = 3, 
m = 8; n = 4, m = 16) with –NH2 and –NMe2 groups at the focal point and on the periphery respectively.
59 
From them, and employing the same methodology as described for dendrimers 10-12, the corresponding 
dendrons [(FluN(Me))Gn(NMe3
+)m]
m+ (n = 2, m = 4 (16); n = 3, m = 8 (17); n = 4, m = 16 (18)) were 
obtained as orange solids soluble in DMSO and water. Again, Kaiser’s tests and 2D-DOSY-NMR spectra 
confirmed the disappearance of the –NH2 moiety and formation of cationic derivatives containing the 
fluorescein fragment (Figure S7, Supporting Information). Furthermore, 2D-TOCSY NMR spectroscopy 
showed the presence of the new chain formed at the focal point (Figure S8, Supporting Information). Also 




Scheme 2. Synthesis of generation 2-4 cationic carbosilane dendrons labelled with fluorescein (Flu) 
[(FluN(Me))Gn(NMe3)m]





Figure 1. Drawing of cationic fluorescein carbosilane dendrimer and dendron of second generation 
(iodide anions are omitted for clarity). 
 
2.2. Biological assays 
Toxicitiy and dendriplex formation 
Previously to biodistribution studies we have evaluated the toxicity of non-labelled dendrimers 
[GnO3(NMe3)m]
m+ (n = 1, m = 6 (19); n = 2, m = 12 (20); n = 3, m =24 (21)),55 labelled dendrimer 
[G2O3(NMeFlu)(NMe3)11]
11+ (11), and labelled dendrons [(FluN(Me))Gn(NMe3)m]
m+ (n = 2, m = 4 (16); 
n = 3, m = 8 (17); n = 4, m =16 (18)), as well as dendriplexes formation with siRNA Nef and toxicity of 




Figure 2. Cytotoxicity (MTT) of [GnO3(NMe3)m]
m+ (n = 1, m = 6 (19); n = 2, m = 12 (20); n = 3, m =24 
(21)) in PBMC after 48 h of treatment with the different nanosystems at various concentrations. Data are 
presented as percent of living cells compared with control cells as 100% of viable cells. Data were 
obtained from three independent experiments. 
Metabolic activity assays of dendrimers 19-21 alone were tested by MTT (Figure 2). Generation-
dependent data were obtained, with cellular viability over 80%, below 20 μM for 19, 5 μM for 20, and 1 
μM for 21. The interaction between dendrimers 19-21 and siRNA Nef was determined by gel 
electrophoresis at time of 24 h (Figure 3). From this study, complete dendriplex formation was observed 
for +/− ratios of 12/1 for 19 and 20 and of 8/1 for 21. Furthermore, cell viability of these dendriplexes 
measured by MTT analyses showed that they were not toxic at the concentration chosen for further 
analyses (100 nM of siRNA Nef corresponding to 8.4 µM for 19, 4.2 µM for 20 and 1.4 µM for 21) 
(Figure S13, Supporting Information). 
 




Nef at different siRNA Nef:dendrimer charge ratios after 24 h (n = 1, m = 6 (19); n = 2, m = 12 (20); n = 
3, m =24 (21)). 
Cationic dendrimer [G2O3(NMeFlu)(NMe3)11]
11+ (11) was chosen to compare the behaviour of non-
labelled and labelled dendrimers with siRNA Nef described in this report, as usually second generation 
carbosilane dendrimers present the best balance between toxicity and activity. Mitochondrial activity 
measured by the MTT assay in PBMCs after treatment with [G2O3(NMeFlu)(NMe3)11]
11+ (11) alone for 
48 hours remained higher than the toxicity limit of 80% up to 5 µM concentration (Figure 4). This value is 
the same than that found for the corresponding non-labelled dendrimer [G2O3(NMe3)12]
12+. Gel 
electrophoresis also showed a similar behavior to that of non-labelled dendrimer 20 in the case of 
interaction between dendrimer [G2O3(NMeFlu)(NMe3)11]
11+ (11) and siRNA (Figure 5). Previously, an 
analogous behaviour of these dendrimers was observed in primary NHA (normal human astrocytes).56 
 
Figure 4. Cytotoxicity (MTT) of [G2O3(NMeFlu)(NMe3)11]
11+ (11) in PBMC after 48 h. Data are 





Figure 5. Dendriplex stability. Electrophoresis gel in agarose of dendriplexes 11/siRNA Nef at different 
siRNA Nef:dendrimer charge ratios after 2 h and 24 h. 
In a similar way than for dendrimers, toxicity and dendriplex formation was studied for fluorescein 
derivatized dendrons [(FluN(Me)Gn(NMe3)m]
m+ (n = 2, m = 4 (16); n = 3, m = 8 (17); n = 4, m =16 (18)). 
The metabolic activity assays of dendrons 16-18 on PBMCs by MTT showed also generation-dependent 
values, with cellular viability over 80% below 20 μM for 16, 10 μM for 17, and 5 μM for 18 (Figure 6). 
With respect to the ability to complex siRNA Nef, the electrophoretic analysis revealed weaker 
interactions between dendrons and siRNA than those observed for dendrimers. In the case of fourth 
generation dendron [(FluN(Me))G4(NMe3)16]
16+ (18), higher stability was observed as consequence of its 
higher charge, although dendriplex formation was only observed when using +/− ratios as higher as 




Figure 6. Cytotoxicity assay (MTT) of [(FluN(Me))Gn(NMe3)m]
m+ (n = 2, m = 4 (16); n = 3, m = 8 
(17); n = 4, m =16 (18)) at different concentrations in PBMC after 48 h. Data are presented as percent of 
living cells compared with control cells as 100% of viable cells. Data are of three independent 
experiments. 
 
Figure 7. Dendriplex stability. Electrophoresis gel in agarose of dendriplexes 
[(FluN(Me))Gn(NMe3)m]
m+/siRNA Nef at different siRNA Nef:dendrimer charge ratios after 48 h (n = 2, 
m = 4 (16); n = 3, m = 8 (17); n = 4, m =16 (18)). 
 
Ex vivo imaging: Analysis of biodistribution by IVIS system 
Taking into account the previous results, the labelled dendritic system used for distribution analysis was 
the second generation dendrimer [G2O3(NMeFITC)(NMe3)11]
11+ (11). Body distribution of this system 
was studied in vivo after systemic administration, using the dendriplex formed between fluorescein-
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labelled dendrimer (11) and siRNA labelled with Cy5.5 (siRNA-Cy5.5) at a ratio 11/siRNA Nef 3/1, and 
comparing with free dendrimer 11 and siRNA-Cy5.5. The fluorescence of dendrimers, siRNA, or 
dendriplex was analyzed using IVIS imaging system (IVIS Gamma Counter Packard 5005, Packard 
Instruments, Meriden, CT). 
 
Figure 8. Distribution of dendrimer 11, siRNA NEF, and dendriplex 11/siRNA (15 mg/Kg) in spleen of 
BALB/c mice after 1 h and 24 h of administration. Analysis of biodistribution by IVIS system. The 
intensity of fluorescence was represented on composite light/fluorescent images by different colors with 
blue color reflecting the lowest fluorescence and red color – the highest intensity. 
In the mouse spleen (Figure 8), which is the responsible of the reticuloendothelial system (RES) for the 
clearance of foreign materials, high accumulation of siRNA-Cy5.5 from the dendriplex was found at 1.h 
post injection (p. i.) that still remained after 24 h, whereas siRNA-Cy5.5 alone was not able to reach this 
organ. In accordance with retention of dendriplex by RES is the important accumulation observed in the 
liver (Figure S14, Supporting Information).  
In the case of treatment with dendrimer 11 alone, its presence in the spleen and liver is showy because it 
is a second generation dendrimer and accumulation in these organs usually occurs for higher generation 
dendrimers as sixth generation PAMAM.61 This fact is probably related with aggregation in aqueous 
medium that could favor longer circulation times.62, 63 
Moreover, the results from these analyses also demonstrated that the 11/siRNA-Cy5.5 nanoparticles 
distributed to and accumulated in the lymph nodes, being the amount of siRNA detected not as higher as 
in the organs mentioned before (Figure 9). At 24 hours it is important to note that the signal does not 
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disappear, confirming the presence of the dendriplex. When kidneys were analyzed, no bioluminescence 
was detected for the dendriplex at any time studied in this localization (Figure S15, Supporting 
Information). It is important to note that dendrimer alone also is well distributed in lymph nodes and in 
kidneys.  
 
Figure 9. Distribution of dendrimer 11, siRNA NEF, and dendriplex 11/siRNA (15 mg/Kg) in lymph 
nodes of BALB/c mice after 1 h and 24 h of administration. Analysis of biodistribution by IVIS system. 
The intensity of fluorescence was represented on composite light/fluorescent images by different colors 
with blue color reflecting the lowest fluorescence and red color – the highest intensity. 
Analysis in tissue sections of dendriplex distribution 
Confocal microscopy was used for histological visualization of the transport and biodistribution of 
dendrimer. For this, the BALB/c mice were systemically injected with the dendrimer, siRNA or 
dendriplex as described above, and 1 h.p.i. sections of OCT-embedded tissues were prepared and analyzed 
by confocal microscopy. As the higher intensity of dendriplex was found in spleen, we then collected this 




Figure 10. Confocal analysis of spleen of mice after different treatments at 1 h.p.i. Nuclei were stained 
with DAPI. 
As shown in the figure, there was not Cy5.5 signal fluorescence in spleen of animal administered with 
fluorescein-dendrimer 11, and indeed the signal in the fluorescein channel was very soft. In the same way, 
we did not detect Cy5.5 in spleen of animals injected with siRNA. However, it was easy to see both 
positive signals for FITC and Cy5.5 in spleen of animals administered with dendriplex, validating the 
dendrimer as siRNA carrier to this organ. 
 
4. Conclusions 
Stable fluorescein-labelled cationic carbosilane dendrimers and dendrons can be obtained following a 
random procedure for the first or a controlled process for the second. In the case of dendrimers, the use of 
thiol-ene addition proved to be very useful for the surface heterofunctionalization, whereas for the 
synthesis of the analogous fluorescein-labelled cationic carbosilane dendrons the use of compounds with a 
-NH2 group at the focal point and –NMe2 groups at the periphery was a suitable choice. All the cationic 
dendritic molecules were soluble in aqueous media, which is very important for biomedical applications. 
The presence of a fluorescein moiety in dendrimers did not modify toxicity neither conditions for 
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dendriplex formation with respect to non-labelled dendrimers. Regarding dendrons, their topology 
hindered the formation of stable dendriplexes, and only a stable system was achieved for fourth generation 
dendron, with sixteen positive charges, at very high +/- ratio. 
Biodistribution studies of a second generation labelled dendrimer 11 show that this dendrimer distribute 
either alone but more importantly complexed with the siRNA into the majority of tissues tested and 
remains relatively stable over 24 hours. This may prove its usefulness in the future for systemic in vivo 
delivery of agents (e.g., DNA or drugs) to numerous tissues.  
 
4. Experimental Section 
4.1. General Considerations. All reactions were carried out under inert atmosphere. NMR spectra were 
recorded on a Varian Unity VXR-300 (300.13 (1H), 75.47 (13C) MHz) or on a Bruker AV400 (400.13 
(1H), 100.60 (13C), 79.49 (29Si) MHz). Chemical shifts (δ) are given in ppm. 1H and 13C resonances were 
measured relative to solvent peaks, considering TMS = 0 ppm.29Si resonances were measured relative to 
external TMS. When necessary, assignment of resonances was done from HSQC, HMBC, COSY, 
TOCSY and NOESY NMR experiments. Elemental analyses were performed on a Perkin-Elmer 240C. 
Mass spectra were obtained from an Agilent 6210 (ESI), a Bruker Ultraflex III (MALDI-TOF) and a 
Thermo Scientific LTQ-FT Ultra (HRMS). Thiol-ene reactions were carried out employing a HPK 125 W 
mercury lamp from HeraeusNoblelight with maximum energy at 365 nm, in normal glassware under inert 
atmosphere.Compounds, HS(CH2)2NH2·HCl, 2,2’-dimethoxy-2-phenylacetophenone (DMPA), MeI, 
NEt3, 5’-isocyanatefluorescein (Aldrich), HS(CH2)2NMe2·HCl (Acros), and K2CO3 (Panreac) were 
obtained from commercial sources.Compounds GnO3Vm (n = 1, m = 6; n = 2, m = 12; n = 3, m = 24)
55and 
NH2Gn(NMe2)m(n = 2, m = 4; n = 3, m = 8)
59 were synthesized as published.  
4.2. Synthesis of compounds. 
In this section the synthesis of first generation dendrimers and second generation dendrons is described. 




Synthesis of [G1O3(NH3Cl)V5] (1).  
G1O3V6 (0.389 g, 0.70 mmol), cysteamine hydrochloride (0.075 g, 0.70 mmol) and 10 mol % of DMPA 
(0.018 g, 0.07 mmol) were combined in 3 ml of ½ THF/methanol solution. The reaction mixture was 
deoxygenated and irradiated for 0.5 h. The reaction mixture was directly used to obtain 4. Compound 1 
could also be aisled with yields around 87 % using a column chromatography in THF with Bio-Beads SX-
1 (Bio-Rad) as stationary phase. 
NMR data (CDCl3): 
1H NMR: δ 0.08 and 0.12 (s, 9 H, SiMe), 0.67 (t, Ja = 8.3 Hz, 6 H, 
OCH2CH2CH2CH2Si), 0.90 (t, Jb = 8.5 Hz, 2 H, SiCH2CH2S), 1.46 (m, 6 H, OCH2CH2CH2CH2Si), 1.76 
(m, 6 H, OCH2CH2CH2CH2Si), 2.55 (t, Jb = 8.5 Hz, 2 H, SiCH2CH2S), 2.89 (m, 2 H, SCH2CH2NH3), 3.20 
(m, 2 H, SCH2CH2NH3), 3.87 (t, Jc = 6.2 Hz, 6 H, OCH2), 5.70 and 6.07 (m, 18 H, SiC2H3 and C6H3O3). 
13C NMR: δ -5.4 (SiMe), 13.6 (OCH2CH2CH2CH2Si), 14.5 (SiCH2CH2S), 20.2 (OCH2CH2CH2CH2Si), 
27.2 (SiCH2CH2S), 28.8 (SCH2CH2N
+), 32.7 (OCH2CH2CH2CH2Si), 39.0 (SCH2CH2N
+), 67.4 (OCH2), 
93.6 (C6H3O3; C-H), 132.8 (SiCHCH2), 136.6 (SiCHCH2), 160.8 (C6H3O3; C-O).  
Synthesis of [G1O3(NH3Cl)(NMe2HCl)5] (4).  
To the reaction mixture of 1, 2-(dimethylamino)ethanothiol hydrochloride (0.497 g, 3.51 mmol) and 
DMPA (0.090 g, 0.35 mmol) were added and the reaction mixture was irradiated for another 3 h and 
monitored by 1H NMR. The final reaction mixture was concentrated by rotatory evaporation and 
redissolved in water. Afterward, it was purified by nanofiltration with a membrane of MWCO = 500. 
Volatiles are removed to get 1 as a white solid (0.660 g, 67 %). 
NMR data (DMSO-d6): 
1H NMR: δ 0.03 (s, 9 H, SiMe), 0.61 (m, 6 H, OCH2CH2CH2CH2Si), 0.88 (m, 
12 H, SiCH2CH2S), 1.40 (m, 6 H, OCH2CH2CH2CH2Si), 1.69 (m, 6 H, OCH2CH2CH2CH2Si), 2.61 (m, 12 
H, SiCH2CH2S), 2.72 (s, 30 H, SCH2CH2NMe2H
+), 2.90 (m, 12 H, SCH2CH2N
+), 3.19 (m, 12 H, 
SCH2CH2N
+), 3.90 (m, 6 H, OCH2), 4.13 (bs, 3 H, -NH3
+), 6.03 (s, 3 H, C6H3O3), 10.85 (bs, 5 H, -
NMe2H












+), 67.5 (OCH2), 94.1 (C6H3O3; C-H), 161.0 (C6H3O3; C-O).
 15N NMR:  -338.3 (-
NMe2H
+). 29Si NMR:  3.1 (G1–SiMe). Anal. Calcd. C55H122Cl6N6O3S6Si3 (1404.96 g/mol): C, 47.02; H, 
8.75; N, 5.98; S, 13.69; Found: C, 46.72; H, 8.44; N, 5.53; S, 13.17.  
Synthesis of [G1O3(NH2)(NMe2)5].  
To a H2O/CH2Cl2 (1:1, 20 ml) mixture of 4 (0.310 g, 0.22 mmol), a NaOH solution was added drop by 
drop (0.063 g, 1.58 mmol). The reaction mixture was stirred for 15 minutes at room temperature, and 
finally the aqueous phase was removed. The organic phase was dried in Na2SO4 and finally filtered and 
evaporated in vacuo to afford G1O3(NH2)(NMe2)6 as a pale yellow oil (0.261 g, 100%).  
NMR data (CDCl3): 
1H NMR: δ 0.02 (s, 9 H, SiMe), 0.58 (m, 6 H, OCH2CH2CH2CH2Si), 0.91 (m, 12 
H, SiCH2CH2S), 1.43 (m, 6 H, OCH2CH2CH2CH2Si), 1.75 (m, 6 H, OCH2CH2CH2CH2Si), 2.23 (s, 30 H, 
SCH2CH2NMe2), 2.49 (m, 12 H, SCH2CH2N), 2.52 (m, 12 H, SiCH2CH2S), 2.59 (m, 10 H, 
SCH2CH2NMe2), 2.82 (m, 2 H, SCH2CH2NH2), 3.88 (m, 6 H, OCH2), 6.03 (s, 3 H, C6H3O3). 
13C NMR: δ 
-5.3 (SiMe), 13.4 (OCH2CH2CH2CH2Si), 14.6 (SiCH2CH2S), 20.4 (OCH2CH2CH2CH2Si), 27.2 
(CH2SCH2CH2NH2), 27.7 (SiCH2CH2S), 29.9 (SCH2CH2NMe2), 33.1 (OCH2CH2CH2CH2Si), 36.3 
(SCH2CH2NH2), 41.2 (SCH2CH2NH2), 45.4 (SiCH2CH2NMe2), 59.3 (SCH2CH2NMe2), 67.4 (OCH2), 93.8 
(C6H3O3; C-H), 160.9 (C6H3O3; C-O).
 15N NMR:  -352.1 (-NMe2). 29Si NMR:  2.4 (G1–SiMe). Anal. 
Calcd. C55H116N6O3S6Si3 (1186.19 g/mol): C, 55.69; H, 9.86; N, 7.08; S, 16.22; Found: C, 55.26; H, 9.53; 
N, 6.97; S, 15.88.  
Synthesis of [G1O3(NMeFlu)(NMe3)5][I]5 (10).  
Over a solution of 4 (0.225 g, 0.16 mmol) in EtOH/THF (8 ml), an excess of FITC (0.066 g, 0.17 mmol) 
and NEt3 (0.22 ml, 1.58 mmol) were added and the mixture was stirred at room temperature in dark for 16 
h. Later on volatiles were removed and the remaining oil was washed with water twice and filtered in THF 
to a new schlenck. An excess of MeI (0.05 ml, 0.80 mmol) was added and the resulting mixture was 
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stirred overnight. Afterward, volatiles were removed and remains were washed with 5 ml of EtOH twice 
and purified by nanofiltration with a membrane of MWCO = 500. The product was obtained as an orange 
solid (0.302 g, 82 %). 
NMR data (DMSO-d6): 
1H NMR: δ 0.05 (s, 9 H, SiMe), 0.63 (m, 6 H, OCH2CH2CH2CH2Si), 0.88 (m, 
12 H, SiCH2CH2S), 1.40 (m, 6 H, OCH2CH2CH2CH2Si), 1.69 (m, 6 H, OCH2CH2CH2CH2Si), 2.42 (bs, 1 
H, SC2H4NHCS), 2.64 (m, 12 H, SiCH2CH2S), 2.80 (s, 3 H, -NHC(S)NMe-), 2.90 (m, 12 H, 
SCH2CH2NMe3
+), 3.10 (s, 45 H, SCH2CH2NMe3
+), 3.54 (m, 12 H, SCH2CH2NMe3
+), 3.89 (t, 6 H, OCH2), 
6.03 (s, 3 H, C6H3O3), 6.55, 6.67 and 7.00 - 8.50 (m, 9 H, CAr-H). 
13C NMR: δ -5.7 (SiMe), 12.3 
(OCH2CH2CH2CH2Si), 13.5 (SiCH2CH2S), 19.3 (OCH2CH2CH2CH2Si), 23.1 (SCH2CH2NMe3
+), 26.3 
(SiCH2CH2S), 32.0 (OCH2CH2CH2CH2Si), 41.8 (-NHC(S)NMe-), 51.7 (SiCH2CH2NMe3
+), 64.0 
(SCH2CH2NMe3
+), 66.7 (OCH2), 93.1 (C6H3O3; C-H), 101.8, 109.3, 112.1, 128.6, 151.4 and 158.9 (CAr-
H), 160.0 (C6H3O3; C-O). 
15N NMR:  -329.9 (-NMe3+). 29Si NMR:  3.3 (G1–SiMe). ). IR (KBr, cm-1): 
υC=O (1752). UV-Vis (H2O): 226.2, 277.2 and 489.5. Anal. Calcd. C82H144I5N7O8Si3 (2299.29 g/mol): C, 
42.83; H, 6.31; N, 4.26; S, 9.76; Found: C, 42.47; H, 6.11; N, 4.11; S, 9.13.  
Synthesis of [(FluN(Me)G2(NMe3)4][I]4 (16).  
Over a solution of NH2G2(NMe2)4 (0.150 g, 0.18 mmol) in EtOH/THF (8 ml) protected from light, an 
excess of FITC (0.090 g, 0.23 mmol) was added following the synthetic procedure described for 10. The 
reaction mixture without further purification was solved in THF and an excess of MeI (0.06 ml, 0.96 
mmol) was added to obtain 16 as an orange solid (0.221 g, 68 %). 
NMR data (DMSO): 1H NMR: δ -0.06 (s, 3 H, SiMe), 0.02 (s, 6 H, SiMe), 0.57 (m, 10 H, 
SiCH2CH2CH2Si and  NCH2CH2CH2CH2Si), 0.85 (m, 8 H, SiCH2CH2S), 1.29 (m, 6 H, 
NCH2CH2CH2CH2Si and SiCH2CH2CH2Si), 1.60 (m, 2 H, NCH2CH2CH2CH2Si), 2.42 (bs, 1 H, -N 
(Me)C(S)NH-), 2.61 (m, 8 H, SiCH2CH2S), 2.88 (m, 8 H, -SCH2CH2NMe3
+), 3.06 (s, 36 H, -
SCH2CH2NMe3
+), 3.28 (m, 2 H, -NCH2), 3.49 (m, 8 H, -SCH2CH2NMe3
+), 6.52, 6.61, and 7.05 - 8.30 30 
(m, 9 H, CAr-H). 
13C NMR: δ -5.6 (SiMe), 12.7 (NCH2CH2CH2CH2Si), 13.6 (SiCH2CH2S), 17.2 – 19.8 
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(NCH2CH2CH2CH2Si and SiCH2CH2CH2Si), 20.6 (NCH2CH2CH2CH2Si), 23.1 (-SCH2CH2NMe3
+), 26.4 
(SiCH2CH2S), 31.4 (NCH2CH2CH2CH2Si), 40.2 (-NCH2), 44.1 (NMeCSNH-),  51.7 (-SiCH2CH2NMe3
+), 
63.9 (SCH2CH2NMe3
+), 101.8, 109.8 and 128.8 (CAr-H).
 15N NMR:  -329.9 (-NMe3+). 29Si NMR:  1.8 
(G1–SiMe), 2.5 (G2–SiMe). IR (KBr): υC=O (1751). UV-vis (H2O): 504.5. ESI: (1278.18 g/mol) q=2 (765.2 
[M-2I-]2+). Anal. Calc. C62H110I4N6O5S5Si3 (1771.77 g/mol): C, 42.03; H, 6.26; N, 4.74; S, 9.05; Found: C, 
42.51; H, 6.69; N, 4.34; S, 9.05.  
4.3 Biomedical assays.  
Primary cell cultures 
Blood samples were obtained from healthy anonymous donors from the transfusion centers of Madrid 
(Spain), following national guidelines. Peripheral blood mononuclear cells (PBMC) were isolated on a 
Ficoll-Hypaque density gradient (Rafer, Zaragoza, Spain) following the current procedures of Spanish 
HIV BioBank.64 PBMC were cultured in RPMI-1640 medium (Gibco, Paisley, UK) containing 10% heat-
inactivated FBS, 1% (2 mM) L-glutamine and antibiotic cocktail (1% ampicillin, 1% cloxacillin and 
0.32% gentamicin; Sigma, St-Louis, MO, USA) at 37°C in a 5% CO2 atmosphere. Prior to compounds 
treatment, PBMC were activated for 48 h with 1 µg/mL of phytohemagglutinin (PHA, Remel, Santa Fe, 
USA) and 60 U/mL of recombinant interleukin-2 (IL-2, Bachem, Bubendorf, Switzerland).  
Dendriplex formation 
Dendriplexes were prepared by mixing dendrimer and siRNA dissolved in sterile water or PBS 
depending on the future study at concentrations depending on the +/- charge ratios and molar 
concentrations desired. After the time indicated, depending on the experiment (2 h, 24 h, or 48 h) 
incubation at room temperature electrophoretic mobility of the mixture was visualized on a 2% (w/v) 
agarose gel at 90 V in a TAE buffer solution (40 mM Tris–HCl, 1% (v/v) acetic acid, and 1mM EDTA). 
The gel bands were quantified using Quantity One 1D Analysis Software (Bio-Rad Laboratories, Inc., 




PBMC were seeded in 96 well plates in OPTIMEM® Imedium containing 10 % FBS (1.5×105 cells in 
190 μl/well) and submitted to the dendrimer at the indicated concentrations. 20 hours later, 20 μl MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide) substrate solution (5 mg/ml) was added to 
the cells to measure mitochondrial activity. After 4 hours, the supernatant was removed and the formed 
crystals were dissolved in 200 μl DMSO and absorbance was measured at 550 nm with a reference of 690 
nm. All points were performed in triplicate. 
Mice 
BALB/c mice, 8 weeks old, were purchased from Charles River Labs (L'Arbresle Cedex, France) and 
they were maintained under specific pathogen-free conditions in the Animal Facility of the Centro de 
Biología Molecular Severo Ochoa (CBMSO-CSIC/HGUGM). All animals were housed 5 per cage and 
maintained on a constant 12 hours light-dark cycles. Food and sterile tap water were available ad lib. All 
mice handling were performed in accordance with the Spanish law of protection of animal life.  
In vivo Imaging 
Mice were anesthetized by inhalation of isoflurane and separately inoculated via retro-orbital injection: 
(1) 200 μL PBS; (2) naked Cy5.5-siRNA-NEF 2,7 μM in 200 μL PBS; (3) 2G-(SNMe3I)11-FITC 15 
mg/kg in 200 μL PBS, and (4) dendriplex 15 mg/kg in 200 μL PBS. Mice were sacrificed 1 and 24 h post-
treatment, and the biodistribution in dissected organs (spleen, lymph nodes, kidneys, and liver) was 
measured using a three-dimensional IVIS Gamma Counter Packard 5005 (Packard Instruments, Meriden, 
CT). These experiments were carried out independently three times. Images were captured under one or 
two channels as indicated: FITC for the dendrimer and Cy5.5 for siRNA NEF. Tissues were placed on 
omnisette tissue cassettes, embedded in optimal cutting temperature (OCT) compound, and frozen in a 
prechilled Dewar flask containing a liquid nitrogen/dry ice slurry for ~1 min until the OCT turned white 
and opaque. Subsequently, the specimens were cut into 10 µm histology slices with a cryostat, and placed 
on a glass slide, and stained with DAPI to label nuclei. 
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Fluorescein-cationic carbosilane dendrimers and dendrons have been synthesized and formation of 
dendriplexes with siRNA Nef have been studied. The biodistribution assays in a model of BALB/c mice 
showed the importance for siRNA of dendriplex formation. 
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